PEGylation of growth hormone-releasing hormone (GRF) analogues

Advanced Drug Delivery Reviews

Volumn 55, Issue 10, 2003, Pages 1279-1291

  Esposito, P ^a   Barbero, L ^a   Caccia, P ^a,c   Caliceti, P ^b   D'Antonio, M ^a   Piquet, G ^a   Veronese, F M ^b  

^a Drug Delivery Systems   (Italy)

^b Department of Pharmaceutical Science ^*  (Italy)

^c IBSA Lugano (CH)   (Switzerland)

Author keywords

GRF PEG biological activity; GRF PEG pharmacodynamics; PEG peptide; PEGylated positional isomers; PEGylated GRF

Indexed keywords

AMINO ACIDS; ENZYMES; HORMONES; ISOMERS; PHARMACODYNAMICS; POLYETHYLENE GLYCOLS; ULTRAFILTRATION;

BIOLOGICAL ACTIVITY; HUMAN RECEPTORS;

DRUG INFUSION;

GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR[1-29]; LYSINE; MACROGOL 10000; MACROGOL 20000; MACROGOL 5000; MACROGOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STABILITY; GROWTH HORMONE BLOOD LEVEL; ISOMER; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SINGLE DRUG DOSE;

EID: 0345283166     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(03)00109-1     Document Type: Article

References (54)

1. Frohman L.A., Jansson J.O. Growth hormone releasing hormone. Endocr. Rev. 7:1986;223-533.
2. Rivier J., Spiess J., Thorner M., Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 300:1982;276-278.
3. Guillemin R., Brazeau P., Boehlen P., Esch F., Ling N., Wehrenberg W. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 218:1982;585-587.
4. Lance V.A., Murphy W.A., Sueiras-Diaz J., Coy D.H. Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochem. Biophys. Res. Commun. 119:1984;265-272.
5. Coy D.H., Murphy W.A., Lance V.A., Heiman M.L. Differential effects of N-terminal modifications on the biological potencies of growth hormone releasing factor analogues with varying chain lengths. J. Med. Chem. 30:1987;219-222.
6. Low L.C. The therapeutic use of growth-hormone-releasing hormone. J. Pediatr. Endocrinol. 6:(1):1993;15-20.
7. Lanes R., Carrillo E. Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. J. Pediatr. Endocrinol. 7:(4):1994;303-308.
8. Chen R.G., Shen Y.N., Yei J., Wang C.F., Xie D.H., Wang X.H., Zhou J.D., Chen C.Y., Wu Y.L., Gunnarsson R. A comparative study of growth hormone (GH) and GH-releasing hormone (1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr. Suppl. 388:1993;32-35.
9. Khorram O. Use of Growth Hormone and Growth Hormone Secretagogues in aging: help or harm. Clin. Obstet. Gynecol. 44:(4):2001;893-901.
10. Walker R., Bercu B. Issues regarding the routine and long term use of growth hormone in anti-aging medicine. Journal of Anti-Aging Medicine. 4:(4):2001;279-300.
11. Frohman L.A., Downs T.R., Williams T.C., Heimer E.P., Pan Y.C., Felix A.M. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J. Clin. Invest. 78:1986;906-913.
12. Bongers J., Lambros T., Ahmad M., Heimer E.P. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim. Biophys. Acta. 1122:1992;147-153.
13. Frohman L.A., Downs T.R., Heimer E.P., Felix A.M. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J. Clin. Invest. 83:1989;1533-1540.
14. US Patent 6.458.764. GRF analogs with increased biological potency.
15. Campbell R.M., Lee Y., Rivier J., Heimer E.P., Felix A.M., Mowles T.F. GRF analogs and fragments: correlation between receptor binding, activity and structure. Peptides. 12:1991;569-574.
16. Coy D.H., Murphy W.A., Lance V.A., Heiman M.L. Strategies in the design of synthetic agonists and antagonists of growth hormone releasing factor. Peptides. 7:1986;49-52.
17. Coy D.H., Murphy W.A., Sueiras-Diaz J., Coy E.J., Lance V.A. Structure-activity studies on the N-terminal region of growth hormone releasing factor. J. Med. Chem. 28:1985;181-185.
18. Rivier J., Rivier C., Galyean R., Yamamoto G., Vale W. Potent long-acting growth hormone releasing factor analogues. Ann. NY. Acad. Sci. 527:1988;4-50.
19. Hernandez J.F., Theobald P.G., Yamamoto G., Andrews J., Rivier C., Vale W., Rivier J.E. Synthesis and biological activity of growth hormone-releasing factor analogues. Rivier J.E., Marshall G.R. Peptides: Chemistry, Structure & Biology. 1990;236-238 ESCOM Science Publishers, Leiden, The Netherlands.
20. Sato K., Hotta M., Kageyama J., Chiang T.C., Hu H.Y., Dong M.H., Ling N. Structure-activity relations of growth hormone-releasing factor (GRF). Pept. Chem. 26:1989;85-90.
21. Felix A.M., Lu Y.A., Campbell R.M. Pegylated peptides. IV. Enhanced biological activity of site-directed pegylated GRF analogs. Int. J. Pept. Protein Res. 46:1995;253-264.
22. Campbell R.M., Heimer E.P., Ahmad M., Eisenbeis H.G., Lambros T.J., Lee Y., Miller R.W., Stricker P.R., Felix A.M. Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo. J. Pept. Res. 49:1997;527-537.
23. a-pegylated peptides using fmoc strategy. Pept. Res. 6:(3):1993;140-146.
24. Lu Y.A., Felix A.M. Pegylated peptides II. Solid-phase synthesis of amino-, carboxy- and side-chain pegylated peptides. Pept. Prot. Res. 43:1994;127-138.
25. Lu Y.A., Felix A.M. Pegylated peptides III. Solid-phase synthesis with pegylating reagents of varying molecular weight: synthesis of multiply pegylated peptides. Reactive Pol. 22:1994;221-229.
26. Katre N.V., Knauf M.J., Laird W.J. Chemical modification of interleukin-2 by poly(ethylene glycol) increases its potency in the murine Meth A Sarcoma model. Proc. Natl. Acad. Sci. USA. 84:1987;1487-1491.
27. Fung W.J., Porter J.E., Bailon P. Strategies for the preparation and chracterization of poly(ethylene glycol) (PEG) conjugated pharmaceutical proteins. Polym. Prep. 38:1997;565-566.
28. Chamow S.M., Kogan T.P., Venuti M., Gadek T., Harris R.J., Peers D.H., Mordenti J., Shak S., Ashkenazi A. Modification of CD4 immunoadhesion IgG with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation. Bioconj. Chem. 5:1994;133-140.
29. Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M., Jacobs S., Clement R.P. A dose finding study of pegylated interferon-alfa-2b and ribavirinin in chronic hepatitis C. Hepatology. 32:2000;647-653.
30. ®) for chronic hepatitis C. A multinational, randomized study. European Association for the Study of Liver Annual Meeting, Rotterdam, 2000.
31. Katre N.V. The conjugation of proteins with polyethylene glycol and other polymers. Altering properties of proteins to enhance their therapeutic potential. Adv. Drug Del. Rev. 10:1993;91-114.
32. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 22:2001;405-417.
33. Bhadra D., Bhadra S., Jain P., Jain N.K. Pegnology: a review of PEGylated systems. Pharmazie. 57:(1):2002;5-29.
34. Hooftman G., Herman S., Schacht E. Review: poly(ethylene glycol)s with reactive endgroups. II. Practical consideration for the preparation of protein-PEG conjugates. J. Bioact. Comp. Pol. 11:1996;135-159.
35. Delgado C., Francis G.E., Malik F., Fisher D., Parkes V. Polymer-derivatized proteins: analytical and preparative problems. Pharm. Sci. 3:1997;59-66.
36. Friedman A.R., Ichhpurani A.K., Brown D.M., Hillman R.M., Krabill L.F., Martin R.A., Zurcher-Neely H.A., Guido D.M. Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Replacement of asparagine residues by serine stabilizes. Int. J. Pept. Res. 37:1991;14-20.
37. Bongers J., Heimer E.P., Lambros T., Lu Y.A., Campbell R.M., Felix A.M. Degradation of aspartic acid and aspragine residues in human growth hormone-releasing factor. Int. J. Pept. Res. 39:1992;364-374.
38. Sakane T., Pardridge W.M. Carboxyl-directed PEGylation of Brain-derived Neurotrophic Factor reduces systemic clearance with minimal loss of biologic activity. Pharm. Res. 14:(8):1997;1085-1109.
39. Zalipsky S., Menon-Rudolph S. Hydrazide derivatives of poly(ethylene glycol) and their bioconjugates, Poly(ethylene glycol) Chemical and Biological applications. Harris J.M., Zalipsky S. ACS Symposium series. 680:1997;318-341.
40. Sartore L., Caliceti P., Schiavon O., Monfardini C., Veronese F.M. Accurate evaluation of the monomethoxy (polyethylene glycol) modified proteins based on amino acid analysis. Appl. Biochem. Biotechnol. 31:1991;213-222.
41. Orsatti L., Veronese F.M. An unusual coupling of poly(ethylene glycol) to tyrosine residues in epidermal growth factor. J. Bioac. Compat. Polym. 14:1999;429-436.
42. Caliceti P., Veronese F.M. Improvement of the physicochemical and biopharmaceutical properties of insulin by poly(ethylene glycol) conjugation. Stp Pharma. Sci. 9:1999;107-113.
43. Kinstler O.B., Brems D.N., Lauren S.L., Paige A.G., Hamburgher J.B., Treuhet M.J. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13:1966;996-1002.
44. Veronese F.M., Caliceti P., Schiavon O. Branched and linear poly(ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J. Bioac. Compat. Polymers. 12:1997;196-207.
45. F.M. Veronese, P. Caliceti, O. Schiavon (1999) Patent Application, WO 99/27897.
46. European Pharmacopoeia, 4th Ed., Residual Solvents - Impurities: Guidelines for residual solvents (CPMP/ICH/283/95) Chapter 5.4 (2002) pp. 459-462.
47. Campbell R.M., Bongers J., Felix A.M. Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor analogues. Biopolymers (Pept. Sci.). 37:1995;67-88.
48. G. Piquet, L. Barbero, S. Traversa, M. Gatti (2002) Patent Application, WO Patent 02/28437.
49. Dubreil P., Brazeau P., Moreau S., Farmer C., Coy D., Abribat T. The use of pigs as animal model to evaluate the efficacy, potency, and specificity of two growth hormone releasing factor analogues. Growth Horm. IGF Res. 11:2001;173-186.
50. Piquet G., Gatti M., Barbero L., Traversa S., Caccia P., Esposito P. Set-up of a large laboratory scale chromatographic separation of poly(ethylene glycol) derivatives of the growth hormone-releasing factor 1-29 analogue. J. Chrom. A. 944:2002;141-148.
51. 2. J. Am. Chem. Soc. 125:2003;3458-3470.
52. M. D'Antonio, S. Canali, I. Louveau, P. Esposito, Pharmacodynamic evaluation of a PEGylated analog of human growth hormone releasing factor in rats and pigs, Growth Horm. IGF Res. (2003) submitted.
53. Böhlen P., Esch F., Brazeau P., Ling N., Guillermin R. Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. Biochem. Biophys. Res. Comm. 116:1983;726-734.
54. Atherton E., Sheppard R.C. Solid Phase Peptide Synthesis. 1986;IRL Press, Oxford, UK.